Connect your AI

Haemonetics HAE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

AbbottABT

$116M-59.6%

MedtronicMDT

$97M-10.2%

ICU MedicalICUI

$0-100%

Agios PharmaceuticalsAGIO

$2.08M+28.4%

LeMaitre VascularLMAT

$2.95M+125%

Bio-Rad LaboratoriesBIO

$3.4M-20.9%

Other financials

Income statement

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

Market cap$3.31B-18.0%

Profitability

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Haemonetics's stock issuance proceeds?: Haemonetics (HAE) reported stock issuance proceeds of $1.15M in Q4 2025.
How has Haemonetics's stock issuance proceeds changed year-over-year?: Haemonetics's stock issuance proceeds increased by 127.1% year-over-year, from $505K to $1.15M.
What is the long-term trend for Haemonetics's stock issuance proceeds?: Over 2 years (2022 to 2024), Haemonetics's stock issuance proceeds has grown at a -17.0% compound annual growth rate (CAGR), from $2.34M to $1.61M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.